Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.23 | -0.47% | 48.49 | 48.50 | 49.38 | 48.63 | 48.30 | 48.32 | 1,434,964 | 22:00:00 |
From Nov 2023 to Nov 2024
By Adria Calatayud
Sanofi said it would end a clinical-development program for its tusamitamab ravtansine drug candidate after a late-stage trial in previously treated patients with nonsmall cell lung cancer didn't meet its primary goal.
The French pharmaceutical company said the decision came after an independent data monitoring committee found that tusamitamab ravtansine as a monotherapy didn't meet its primary goal of progression-free survival compared to docetaxel. The trial had dual primary goals of progression-free survival and overall survival.
While overall survival improved, the decision on the trial was based on a lack of improvement on progression-free survival, Sanofi said Thursday.
Tusamitamab ravtansine had a similar safety profile as previously presented, the company said.
Sanofi said it will continue exploring the potential of tusamitamab-based antibody drug conjugates and research on the potential of certain molecules as biomarkers in several types of cancer.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
December 21, 2023 02:10 ET (07:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
